On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

Major companies like pharma giant GlaxoSmithKline (GSK) have established their largest ... holiday and it’s great to see key players from our ecosystem and across Europe hosting a stellar line up of ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.

This segment also grew, mainly due to their expanded approvals for new indications in the US and Europe. Lastly, GSK’s general medicines segment includes treatments like Trelegy for asthma and ...

Richard Staines heard about this new strategy at the Veeva 2019 Commercial and Medical Summit, Europe. GSK’s approach to marketing content has had a major rethink in the last two years ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...